Dazodalibep seen to ease Sjögren’s syndrome symptoms in Phase 2 trial
Dazodalibep, Horizon Therapeutics’ experimental therapy for Sjögren’s syndrome, was found to safely and effectively ease disease activity and symptoms across two divergent groups of people with the chronic autoimmune disorder. These groups included people with Sjögren’s who had generally been excluded from recent clinical trials — patients with…